[DOI] [PMC free article] [PubMed] [Google Scholar] Wild AC, Mulcahy RT
University of Toronto pharmaceutical policy expert Mina Tadrous estimates patients could see pricing as low as $100-$150 per month , representing approximately 35-50% of current Ozempic costs . Realistic Timeline: While the patent expired in early January 2026, experts caution that approval timelines remain uncertain
Dacic, S, Cao, X, Bota Rabassedas, MN, Sanchez Espiridion, B, Berezowska, S, Han, Y, Chung, JH, Beasley, MB, Dongmei, L, Hwang, D, Mino-Kenudson, M, Minami, Y, Papotti, M, Rekhtman, N, Roden, AC, Thunnissen, E, Tsao, MS, Yatabe, Y, Yoshida, A, Wang, L , Hartman, DJ, Jerome, JA, Kadara, HN, Chou, TY, Wistuba, II
pmid:23755725 15
Diagnosis typically involves measuring thyroid stimulating hormone (TSH) as the first-line test, with elevated TSH and low free T4 confirming hypothyroidism